Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Omega Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L..." |
|
| 07/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/10/2023 |
SC 13G/A
| FMR LLC reports a 10.1% stake in OMEGA THERAPEUTICS INC |
| 03/01/2023 |
8-K
| Quarterly results |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
SC 13D/A
| Flagship Ventures Fund V, L.P. reports a 53.2% stake in OMEGA THERAPEUTICS, INC. |
| 02/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 9.6% stake in OMEGA THERAPEUTICS INC |
| 11/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/08/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results|
Docs:
|
"Omega Therapeutics, Inc. Condensed consolidated statements of operations and comprehensive loss Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Collaboration revenue from related party $ 476 $ — $ 743 $ — Operating expenses: Research and development 19,387 11,184 33,659 20,933 General and administrative 6,202 3,637 11,336 6,452 Related party expense, net 741 384 1,562 763 Total operating expenses 26,330 15,205 46,557 28,148 Loss from operations Other expense, net: Interest expense, net Change in fair value of warrant liability — — Other expense, net Total other expense, net Net loss $ $ $ $ Net loss per common stock attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average common stock used in net loss per share attributable to common..." |
|
| 06/09/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/04/2022 |
8-K
| Quarterly results|
Docs:
|
"Omega Therapeutics, Inc. Condensed consolidated statements of operations and comprehensive loss Three Months Ended March 31, 2022 2021 Collaboration revenue from related party $ 268 $ — Operating expenses: Research and development 14,191 9,748 General and administrative 5,406 2,745 Related party expense, net 630 449 Total operating expenses 20,227 12,942 Loss from operations Other expense, net: Interest expense, net Change in fair value of warrant liability — Other expense, net Total other expense, net Net loss $ $ Net loss per common stock attributable to common stockholders, basic and diluted $ $ Weighted-average common stock used in net loss per share attributable to common stockholders, basic and diluted 47,807,209 4,496,657 Comprehensive loss: Net loss $ $ Other comprehensive loss..." |
|
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|
|
|